Abstract
Objective: We previously reported a triage algorithm to identify women at high risk of poor operative outcomes to successfully improve surgical outcomes after cytoreductive surgery (CRS) for advanced epithelial ovarian cancer (EOC). This provides a sensible, evidence-based approach to triage between neoadjuvant chemotherapy (NACT) and CRS rather than subjective bias or institutional preference. We sought to independently validate the performance of our algorithm using national multiinstitutional data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
